GO:0006691 leukotriene metabolic process: Pathway and Genes

Leukotriene metabolic process (GO:0006691) is the biological process encompassing the chemical reactions and pathways involving leukotrienes, a family of pharmacologically active lipid mediators derived from polyunsaturated fatty acids such as arachidonic acid. These eicosanoids are synthesized primarily in leukocytes and other inflammatory cells and act as potent autocrine and paracrine signals in inflammation, immunity, and tissue homeostasis. The pathway is initiated by 5-lipoxygenase (ALOX5), which oxygenates arachidonic acid to form the unstable intermediate leukotriene A4 (LTA4). LTA4 is then converted by LTA4 hydrolase (LTA4H) to leukotriene B4 (LTB4), a powerful neutrophil chemoattractant, or by LTC4 synthase (LTC4S) to leukotriene C4 (LTC4), the parent cysteinyl leukotriene. Subsequent metabolism of cysteinyl leukotrienes involves gamma-glutamyl transpeptidase and dipeptidases to yield LTD4 and LTE4, which are further processed through the mercapturic acid pathway. Beta-oxidation also contributes to leukotriene catabolism, particularly in peroxisomes. For researchers, GO:0006691 provides a structured framework to study lipid mediator biosynthesis, signal termination, and the role of leukotrienes in human disease. Dysregulated leukotriene metabolism is linked to asthma, allergic inflammation, kidney diseases, and anaphylaxis. The pathway is also a validated drug target: inhibitors of ALOX5, ALOX5AP, and cysteinyl leukotriene receptors are used clinically, and LTA4H inhibitors are under investigation. Understanding the enzymatic steps, subcellular organization, and regulatory checkpoints of leukotriene metabolism is therefore essential for both basic immunology and translational medicine. This article integrates the QuickGO definition of GO:0006691 with verified PubMed literature to provide a research-grade overview of the pathway, its key genes, disease relevance, and experimental strategies, including CRISPR-based models for functional genomics.

GO:0006691 leukotriene metabolic process is defined as the chemical reactions and pathways involving leukotriene, a pharmacologically active substance derived from a polyunsaturated fatty acid, such as arachidonic acid. In practice, this includes the biosynthesis of leukotrienes from arachidonic acid via 5-lipoxygenase, the conversion of the intermediate LTA4 to LTB4 or LTC4, the sequential metabolism of cysteinyl leukotrienes to LTD4 and LTE4, and their further catabolism through beta-oxidation and the mercapturic acid pathway.

Leukotriene metabolic process is critically important because leukotrienes are among the most potent lipid mediators of inflammation and immunity, and their dysregulation contributes to prevalent human diseases such as asthma, allergic rhinitis, anaphylaxis, and kidney injury. The pathway is also a proven source of drug targets: 5-lipoxygenase inhibitors, 5-lipoxygenase-activating protein inhibitors, and cysteinyl leukotriene receptor antagonists are used to treat asthma and allergic conditions. Moreover, recent evidence shows that cysteinyl leukotrienes stimulate gut absorption of food allergens to promote anaphylaxis in mice, highlighting new roles in food allergy and barrier function. Understanding GO:0006691 therefore informs both mechanistic immunology and therapeutic development.

The following genes encode enzymes and accessory proteins that directly participate in or regulate leukotriene metabolic process (GO:0006691).

Leukotriene metabolic process is regulated at multiple levels. Substrate availability is controlled by cytosolic phospholipase A2 (PLA2G4A), which releases arachidonic acid from membrane phospholipids in response to calcium signals. ALOX5 activity is regulated by calcium, ATP, and its interaction with ALOX5AP at the nuclear membrane. Transcriptional regulation of ALOX5, LTA4H, and LTC4S occurs in response to inflammatory stimuli, and post-translational modifications such as phosphorylation can modulate enzyme activity. The balance between LTB4 and cysteinyl leukotriene production is determined by the relative expression and activity of LTA4H and LTC4S. Catabolic regulation includes beta-oxidation and omega-hydroxylation, which terminate leukotriene signaling. Additionally, the pathway is influenced by cellular redox status and by feedback from leukotriene receptors.

Cysteinyl leukotrienes are central mediators of bronchoconstriction, mucus secretion, and airway edema in asthma. LTC4S and CysLT1R are validated drug targets, and genetic variants in ALOX5, ALOX5AP, LTA4H, and LTC4S have been associated with asthma susceptibility and treatment response. Targeting leukotriene metabolic enzymes with CRISPR knockout models can clarify their causal roles in airway inflammation.

Recent evidence demonstrates that cysteinyl leukotrienes stimulate gut absorption of food allergens to promote anaphylaxis in mice, identifying a novel role for leukotriene metabolism in food allergy. This finding suggests that enzymes such as LTC4S and LTA4H may be therapeutic targets for preventing allergen uptake and systemic anaphylaxis.

Leukotrienes and their receptors are implicated in kidney diseases, including glomerulonephritis, diabetic nephropathy, and ischemia-reperfusion injury. LTB4 promotes neutrophil infiltration, while cysteinyl leukotrienes contribute to vascular permeability and fibrosis. Experimental models with LTA4H or LTC4S knockout can help define their contributions to renal pathology.

Leukotriene metabolic process has been linked to atherosclerosis, inflammatory bowel disease, and rheumatoid arthritis through its effects on leukocyte recruitment and vascular function. The pathway also interacts with other eicosanoid networks, and its dysregulation can shift inflammatory tone. CRISPR-based screens in immune cells can identify novel regulators of leukotriene production relevant to these conditions.

Targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for quantifying leukotrienes (LTB4, LTC4, LTD4, LTE4) in cell culture supernatants, tissues, and biological fluids. Stable isotope-labeled internal standards enable precise quantification. This method is essential for validating CRISPR knockout or overexpression effects on leukotriene metabolic flux.

Enzymatic activities of ALOX5, LTA4H, and LTC4S can be measured using substrate-based assays with UV or fluorescence detection. For LTA4H, both epoxide hydrolase and aminopeptidase activities can be monitored. These assays provide direct functional readouts for point mutations or knock-in models.

RNA-seq and quantitative proteomics can profile expression of leukotriene pathway genes across cell types and conditions. These approaches help identify regulatory mechanisms and off-target effects in CRISPR-edited cells. Phosphoproteomics can reveal post-translational regulation of ALOX5 and LTA4H.

Fluorescence microscopy with tagged enzymes (e.g., GFP-ALOX5, mCherry-LTC4S) reveals nuclear envelope localization and co-localization with ALOX5AP. Live-cell imaging can track leukotriene release and receptor activation. These methods are valuable for studying spatial organization of the pathway.

Researchers studying leukotriene metabolic process-related genes often need to determine whether a candidate gene is causally involved in leukotriene production, degradation, or signaling. CRISPR-based genome editing provides a precise way to test these hypotheses by creating isogenic knockout, point-mutation, knock-in, or overexpression models. EDITGENE specializes in these services for lipid mediator and inflammation research.

Leukotriene metabolic process (GO:0006691) is a central lipid mediator pathway with profound implications for inflammation, immunity, and human disease. The enzymatic steps catalyzed by ALOX5, ALOX5AP, LTA4H, and LTC4S, along with catabolic and transport processes, determine the balance of leukotrienes that drive asthma, anaphylaxis, and kidney pathology. Recent discoveries continue to expand the roles of cysteinyl leukotrienes in food allergy and barrier function. CRISPR-based functional genomics offers a powerful approach to dissect the causal roles of leukotriene pathway genes and to identify new therapeutic targets. EDITGENE provides comprehensive knockout, point-mutation, knock-in, overexpression, and library screening services to accelerate this research.